gemcitabine 100mg/ml concentrate for solution for infusion - 20ml vial
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - gemcitabine - concentrate for solution for infusion - gemcitabine 2000 mg - antineoplastic agents
gemcitabine ebewe 1000mg/100ml concentrate for solution for infusion
gemcitabine hydrochloride - concentrate for solution for infusion - 1 ml contains 11.4 mg gemcitabine hydrochloride - gemcitabine
gemcitabine ebewe 200mg/20ml concentrate for solution for infusion
gemcitabine hydrochloride - concentrate for solution for infusion - 1 ml contains 11.4 mg gemcitabine hydrochloride - gemcitabine
gemcitabine hydrochloride injection powder lyophilized for solution
sun pharma global fze - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 200 mg in 5 ml
gemcitabine hydrochloride injection, powder, lyophilized, for solution
heritage pharmaceuticals inc. - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib), or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine is indicated for patients previously treated with fluorouracil. gemcitabine for injection usp is contraindicated in patients with a known hypersensitivity to gemcitabine.
gemcitabine- gemcitabine injection, solution
sagent pharmaceuticals - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib), or metastatic (stage iv) non-small cell lung cancer. gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with 5-fu. gemcitabine injection is contraindicated in patients with a known hyperse
gemcitabine hydrochloride injection powder lyophilized for solution
hameln rds gmbh - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 200 mg in 5 ml
gemcitabine hydrochloride injection powder lyophilized for solution
watson laboratories, inc. - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 200 mg in 5 ml
gemcitabine- gemcitabine hydrochloride injection
armas pharmaceuticals inc. - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with fluorouracil. gemcitabine injection is contraindicated in patients with a kn
gemcitabine- gemcitabine hydrochloride injection
armas pharmaceuticals inc. - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with fluorouracil. gemcitabine injection is contraindicated in patients with a kn